The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection

go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342CrossRefPubMed

go back to reference Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z (2010) Hepatitis C treatment: current and future perspectives. Virol J 7:296CrossRefPubMedCentralPubMed Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z (2010) Hepatitis C treatment: current and future perspectives. Virol J 7:296CrossRefPubMedCentralPubMed

go back to reference Poynard T, Yuen MF, Ratziu V, Lai CL (2003) Viral hepatitis C. Lancet 362:2095–2100CrossRefPubMed Poynard T, Yuen MF, Ratziu V, Lai CL (2003) Viral hepatitis C. Lancet 362:2095–2100CrossRefPubMed

go back to reference Lawitz E, Gane EJ (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 369:678–679CrossRefPubMed Lawitz E, Gane EJ (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 369:678–679CrossRefPubMed

go back to reference Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370:211–221CrossRefPubMed Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370:211–221CrossRefPubMed

go back to reference Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC (2014) The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 39:518–531CrossRefPubMed Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC (2014) The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 39:518–531CrossRefPubMed

go back to reference Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD (2014) Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. Incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 161:546–553CrossRefPubMed Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD (2014) Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. Incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 161:546–553CrossRefPubMed

go back to reference Aman W, Mousa S, Shiha G, Mousa SA (2012) Current status and future directions in the management of chronic hepatitis C. Virol J 9:57CrossRefPubMedCentralPubMed Aman W, Mousa S, Shiha G, Mousa SA (2012) Current status and future directions in the management of chronic hepatitis C. Virol J 9:57CrossRefPubMedCentralPubMed

go back to reference Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567CrossRefPubMed Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567CrossRefPubMed

go back to reference Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ (2007) Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol 81:5882–5892CrossRefPubMedCentralPubMed Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ (2007) Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol 81:5882–5892CrossRefPubMedCentralPubMed

go back to reference Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B (2000) Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578–582CrossRefPubMed Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B (2000) Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578–582CrossRefPubMed

go back to reference Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395–1406CrossRefPubMedCentralPubMed Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395–1406CrossRefPubMedCentralPubMed

go back to reference Zubkova I, Duan H, Wells F, Mostowski H, Chang E, Pirollo K, Krawczynski K, Lanford R, Major M (2014) Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees. Hepatology 59:803–813CrossRefPubMedCentralPubMed Zubkova I, Duan H, Wells F, Mostowski H, Chang E, Pirollo K, Krawczynski K, Lanford R, Major M (2014) Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees. Hepatology 59:803–813CrossRefPubMedCentralPubMed

go back to reference Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O’Gorman M, Beaman K, Cotler SJ, Hershow R, Rong L (2009) Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 6:46CrossRefPubMedCentralPubMed Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O’Gorman M, Beaman K, Cotler SJ, Hershow R, Rong L (2009) Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 6:46CrossRefPubMedCentralPubMed

go back to reference Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J (2008) Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol 82:3438–3451CrossRefPubMedCentralPubMed Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J (2008) Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol 82:3438–3451CrossRefPubMedCentralPubMed

go back to reference Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S (2010) Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 44:140–145CrossRefPubMed Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S (2010) Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 44:140–145CrossRefPubMed

go back to reference Kobayashi K, Ishii M, Shiina M, Ueno Y, Kondo Y, Kanno A, Miyazaki Y, Yamamoto T, Kobayashi T, Niitsuma H, Kikumoto Y, Takizawa H, Shimosegawa T (2005) Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss. Clin Exp Immunol 141:81–88CrossRefPubMedCentralPubMed Kobayashi K, Ishii M, Shiina M, Ueno Y, Kondo Y, Kanno A, Miyazaki Y, Yamamoto T, Kobayashi T, Niitsuma H, Kikumoto Y, Takizawa H, Shimosegawa T (2005) Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss. Clin Exp Immunol 141:81–88CrossRefPubMedCentralPubMed

go back to reference Singh R, Kaul R, Kaul A, Khan K (2007) A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 13:1770–1787CrossRefPubMedCentralPubMed Singh R, Kaul R, Kaul A, Khan K (2007) A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 13:1770–1787CrossRefPubMedCentralPubMed

go back to reference McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D (2004) Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40:108–114CrossRefPubMed McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D (2004) Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40:108–114CrossRefPubMed

go back to reference Harris RA, Sugimoto K, Kaplan DE, Ikeda F, Kamoun M, Chang KM (2008) Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology 48:70–79CrossRefPubMedCentralPubMed Harris RA, Sugimoto K, Kaplan DE, Ikeda F, Kamoun M, Chang KM (2008) Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology 48:70–79CrossRefPubMedCentralPubMed

go back to reference Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O’Brien SJ, Karacki P, Marti D, Astemborski J, Carrington M (2001) Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 184:16–21CrossRefPubMed Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O’Brien SJ, Karacki P, Marti D, Astemborski J, Carrington M (2001) Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 184:16–21CrossRefPubMed

go back to reference Middleton D, Menchaca L, Rood H, Komerofsky R (2003) New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61:403–407 Middleton D, Menchaca L, Rood H, Komerofsky R (2003) New allele frequency database: http://​www.​allelefrequencie​s.​net. Tissue Antigens 61:403–407

go back to reference Cheng LH, Jin SZ, Gao SQ, Li Z, Zou HY, Wang DM, Wu GG (2005) Difference in HLA-A*02 allele distribution between Han populations in south and north China. Di Yi Jun Yi Da Xue Xue Bao 25:321–324PubMed Cheng LH, Jin SZ, Gao SQ, Li Z, Zou HY, Wang DM, Wu GG (2005) Difference in HLA-A*02 allele distribution between Han populations in south and north China. Di Yi Jun Yi Da Xue Xue Bao 25:321–324PubMed

go back to reference Kondo Y, Kobayashi K, Kobayashi T, Shiina M, Ueno Y, Satoh T, Shimosegawa T (2003) Distribution of the HLA class I allele in chronic hepatitis C and its association with serum ALT level in chronic hepatitis C. Tohoku J Exp Med 201:109–117CrossRefPubMed Kondo Y, Kobayashi K, Kobayashi T, Shiina M, Ueno Y, Satoh T, Shimosegawa T (2003) Distribution of the HLA class I allele in chronic hepatitis C and its association with serum ALT level in chronic hepatitis C. Tohoku J Exp Med 201:109–117CrossRefPubMed

go back to reference (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55:245–264 (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55:245–264

go back to reference Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293CrossRefPubMed Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293CrossRefPubMed

go back to reference Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E (2011) Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther 16:1073–1080CrossRefPubMed Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E (2011) Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther 16:1073–1080CrossRefPubMed

go back to reference Dai CY, Chuang WL, Hsieh MY, Huang JF, Lin YY, Chu PY, Hou NJ, Lin ZY, Chen SC, Wang LY, Yu ML (2010) Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res 85:396–402CrossRefPubMed Dai CY, Chuang WL, Hsieh MY, Huang JF, Lin YY, Chu PY, Hou NJ, Lin ZY, Chen SC, Wang LY, Yu ML (2010) Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res 85:396–402CrossRefPubMed

go back to reference McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361:580–593CrossRefPubMed McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361:580–593CrossRefPubMed

go back to reference Boghdadi G, Seleem WM (2014) Differential expression of Toll-like receptors 7 & 8 mRNA in monocytes of patients with chronic hepatitis C infection: correlation with interferon and ribavirin treatment. Egypt J Immunol 21:67–75PubMed Boghdadi G, Seleem WM (2014) Differential expression of Toll-like receptors 7 & 8 mRNA in monocytes of patients with chronic hepatitis C infection: correlation with interferon and ribavirin treatment. Egypt J Immunol 21:67–75PubMed

go back to reference Imran M, Manzoor S, Parvaiz F (2014) Predictive potential of IL-18 -607 and osteopontin −442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol 27:404–411CrossRefPubMed Imran M, Manzoor S, Parvaiz F (2014) Predictive potential of IL-18 -607 and osteopontin −442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol 27:404–411CrossRefPubMed

go back to reference Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G (2014) IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol 61:235–241CrossRefPubMed Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G (2014) IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol 61:235–241CrossRefPubMed

go back to reference Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O’Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Jr., Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Jr., Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Jr., Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, McLeod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O’Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, 3rd, Olender SA, Ostrowski M, Owen WF, Jr., Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Jr., Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van’t Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551–1557 Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O’Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Jr., Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Jr., Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Jr., Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, McLeod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O’Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, 3rd, Olender SA, Ostrowski M, Owen WF, Jr., Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Jr., Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van’t Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551–1557

go back to reference Song H, Pavlicek JW, Cai F, Bhattacharya T, Li H, Iyer SS, Bar KJ, Decker JM, Goonetilleke N, Liu MK, Berg A, Hora B, Drinker MS, Eudailey J, Pickeral J, Moody MA, Ferrari G, McMichael A, Perelson AS, Shaw GM, Hahn BH, Haynes BF, Gao F (2012) Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology 9:89CrossRefPubMedCentralPubMed Song H, Pavlicek JW, Cai F, Bhattacharya T, Li H, Iyer SS, Bar KJ, Decker JM, Goonetilleke N, Liu MK, Berg A, Hora B, Drinker MS, Eudailey J, Pickeral J, Moody MA, Ferrari G, McMichael A, Perelson AS, Shaw GM, Hahn BH, Haynes BF, Gao F (2012) Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology 9:89CrossRefPubMedCentralPubMed

go back to reference Shea PR, Shianna KV, Carrington M, Goldstein DB (2013) Host genetics of HIV acquisition and viral control. Annu Rev Med 64:203–217CrossRefPubMed Shea PR, Shianna KV, Carrington M, Goldstein DB (2013) Host genetics of HIV acquisition and viral control. Annu Rev Med 64:203–217CrossRefPubMed

go back to reference Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, Yasukawa M, Taylor G, Bangham CR, Asquith B (2010) HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog 6:e1001117CrossRefPubMedCentralPubMed Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, Yasukawa M, Taylor G, Bangham CR, Asquith B (2010) HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog 6:e1001117CrossRefPubMedCentralPubMed

go back to reference Khakoo SI, Carrington M (2006) KIR and disease: a model system or system of models? Immunol Rev 214:186–201CrossRefPubMed Khakoo SI, Carrington M (2006) KIR and disease: a model system or system of models? Immunol Rev 214:186–201CrossRefPubMed

go back to reference Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE (2013) HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol 191:1567–1577CrossRefPubMedCentralPubMed Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE (2013) HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol 191:1567–1577CrossRefPubMedCentralPubMed

go back to reference Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA (2012) Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine 30:2146–2152CrossRefPubMedCentralPubMed Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA (2012) Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine 30:2146–2152CrossRefPubMedCentralPubMed

go back to reference Poland GA, Ovsyannikova IG, Jacobson RM (2008) Immunogenetics of seasonal influenza vaccine response. Vaccine 26(Suppl 4):D35–D40CrossRefPubMedCentralPubMed Poland GA, Ovsyannikova IG, Jacobson RM (2008) Immunogenetics of seasonal influenza vaccine response. Vaccine 26(Suppl 4):D35–D40CrossRefPubMedCentralPubMed

go back to reference Lancaster T, Sanders E, Christie JM, Brooks C, Green S, Rosenberg WM (2002) Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection. J Viral Hepat 9:18–28CrossRefPubMed Lancaster T, Sanders E, Christie JM, Brooks C, Green S, Rosenberg WM (2002) Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection. J Viral Hepat 9:18–28CrossRefPubMed

go back to reference Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109CrossRefPubMed Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109CrossRefPubMed

go back to reference Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D’Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G (2012) HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol 12:162CrossRefPubMedCentralPubMed Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D’Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G (2012) HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol 12:162CrossRefPubMedCentralPubMed

go back to reference Kim IH (2010) Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response. Korean J Hepatol 16:201–205CrossRefPubMed Kim IH (2010) Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response. Korean J Hepatol 16:201–205CrossRefPubMed

go back to reference Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W (2013) A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. Eur J Gastroenterol Hepatol 25:601–605CrossRefPubMed Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W (2013) A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. Eur J Gastroenterol Hepatol 25:601–605CrossRefPubMed

go back to reference Zhou JY, Jiang ZA, Zhou DF, Xing WL, Wang W, Wang YD (2013) Virological responses in chronic hepatitis C patients undergoing prolonged therapy with low-dose Peg-IFNalpha-2a. Hepatogastroenterology 60:301–304PubMed Zhou JY, Jiang ZA, Zhou DF, Xing WL, Wang W, Wang YD (2013) Virological responses in chronic hepatitis C patients undergoing prolonged therapy with low-dose Peg-IFNalpha-2a. Hepatogastroenterology 60:301–304PubMed

go back to reference Sarwar S, Ryan EJ, Iqbal M, McCormick PA, O’Farrelly C, Hegarty J (2012) Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection. Ir J Med Sci 181:53–58CrossRefPubMed Sarwar S, Ryan EJ, Iqbal M, McCormick PA, O’Farrelly C, Hegarty J (2012) Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection. Ir J Med Sci 181:53–58CrossRefPubMed

go back to reference Peng CY, Chen TH, Lim YP, Tsai FJ, Lin WY, Liao WL, Wan L (2014) Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study. BMC Gastroenterol 14:113CrossRefPubMedCentralPubMed Peng CY, Chen TH, Lim YP, Tsai FJ, Lin WY, Liao WL, Wan L (2014) Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study. BMC Gastroenterol 14:113CrossRefPubMedCentralPubMed

go back to reference Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100–1104CrossRefPubMed Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100–1104CrossRefPubMed

go back to reference Mangia A, Mottola L, Santoro R (2013) Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol 19:8924–8928CrossRefPubMedCentralPubMed Mangia A, Mottola L, Santoro R (2013) Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol 19:8924–8928CrossRefPubMedCentralPubMed

go back to reference Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54:415–421CrossRefPubMed Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54:415–421CrossRefPubMed

go back to reference Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801CrossRefPubMedCentralPubMed Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801CrossRefPubMedCentralPubMed

go back to reference Chen H, Zhang Y, Huang P, Xu Y, Wang J, Su J, Yu R (2014) Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. J Biomed Res 28:476–483PubMedCentralPubMed Chen H, Zhang Y, Huang P, Xu Y, Wang J, Su J, Yu R (2014) Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. J Biomed Res 28:476–483PubMedCentralPubMed

go back to reference Mi Y, Gao YT, Jiao XL, Guo H, Liu T, Jing L, Shi WX, Du Z (2014) The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon 14:e18793CrossRefPubMedCentralPubMed Mi Y, Gao YT, Jiao XL, Guo H, Liu T, Jing L, Shi WX, Du Z (2014) The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon 14:e18793CrossRefPubMedCentralPubMed

go back to reference Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD, Xie Q (2014) IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in Chinese Han population. J Dig Dis 14(10):1111 Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD, Xie Q (2014) IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in Chinese Han population. J Dig Dis 14(10):1111

go back to reference Liu T, Sha K, Yang L, Wang Y, Zhang L, Liu X, Yang F (2014) IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS One 9:e91316CrossRefPubMedCentralPubMed Liu T, Sha K, Yang L, Wang Y, Zhang L, Liu X, Yang F (2014) IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS One 9:e91316CrossRefPubMedCentralPubMed

go back to reference Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ (2010) Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 53:616–623CrossRefPubMed Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ (2010) Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 53:616–623CrossRefPubMed

go back to reference Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Rajender Reddy K (2014) Safety profile of boceprevir and telaprevir in chronic hepatitis C: real-world experience from HCV-TARGET. J Hepatol 10:168–180 Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Rajender Reddy K (2014) Safety profile of boceprevir and telaprevir in chronic hepatitis C: real-world experience from HCV-TARGET. J Hepatol 10:168–180

go back to reference Ferreira PR, da Silva MH, Brandao-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC (2014) The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. Br J Infect Dis 14:166–174 Ferreira PR, da Silva MH, Brandao-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC (2014) The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. Br J Infect Dis 14:166–174

go back to reference Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365:1014–1024CrossRefPubMed Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365:1014–1024CrossRefPubMed

go back to reference Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207–1217CrossRefPubMedCentralPubMed Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207–1217CrossRefPubMedCentralPubMed

go back to reference Pawlotsky JM (2011) The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140:746–754CrossRefPubMed Pawlotsky JM (2011) The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140:746–754CrossRefPubMed

go back to reference Reau NS, Jensen DM (2014) Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 59:1246–1249CrossRefPubMed Reau NS, Jensen DM (2014) Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 59:1246–1249CrossRefPubMed

go back to reference Mao Wenhui, Chen Wen, Wei Lai (2012) Cost-effectiveness analysis of Peg-interferon Alpha-2a plus ribavirin vs. conventional interferon plus ribavirin for the treatment of chronic hepatitis C in China. China J Pharm Econ 15:6–14 Mao Wenhui, Chen Wen, Wei Lai (2012) Cost-effectiveness analysis of Peg-interferon Alpha-2a plus ribavirin vs. conventional interferon plus ribavirin for the treatment of chronic hepatitis C in China. China J Pharm Econ 15:6–14

go back to reference Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R (2013) Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57:2164–2170CrossRefPubMedCentralPubMed Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R (2013) Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 57:2164–2170CrossRefPubMedCentralPubMed

go back to reference Yu ML, Chuang WL (2009) Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 24:336–345CrossRefPubMed Yu ML, Chuang WL (2009) Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 24:336–345CrossRefPubMed

go back to reference Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML (2012) Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 56:34–40CrossRefPubMed Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML (2012) Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 56:34–40CrossRefPubMed